Letters Section Editor: Jody W. Zylke, MD, Senior Editor.
Author Affiliations: Porto Alegre Epilepsy Surgery Program, Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil (firstname.lastname@example.org).
To the Editor: Dr Engel and colleagues1 presented important additional evidence on the superiority of surgical therapy over antiepileptic drugs (AEDs) in the treatment of refractory mesial temporal lobe epilepsy (MTLE). Their results corroborate and expand the findings of a previous randomized controlled trial,2 which led the American Academy of Neurology to issue a practice parameter in 2003 recommending surgery as the treatment of choice for pharmacoresistant MTLE.3
Kieling RR, Palmini A, Paglioli E. Treatment of Refractory Mesial Temporal Lobe Epilepsy. JAMA. 2012;307(23):2483–2485. doi:10.1001/jama.2012.4985
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: